Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof

Abstract

The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and/or extracellular matrix (ECM).

1 .- 20 . (canceled) 
     
     
         21 . A method for preventing or treating Fuch's endothelial corneal dystrophy in a subject, comprising administering an effective amount of rapamycin to the subject. 
     
     
         22 . The method of  claim 21 , wherein the rapamycin is administered as an eye drop. 
     
     
         23 . The method of  claim 22 , wherein the rapamycin has a concentration of at least about 0.1 nM in the eye drop. 
     
     
         24 . The method of  claim 22 , wherein the rapamycin has a concentration of at least about 0.1 mM in the eye drop.